US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Nasus Pharma Ltd.

3.35

-0.2000-5.63%

Post-market: 3.350.00000.00%16:10 EDT

Volume:10.71K

Turnover:36.09K

Market Cap:39.39M

PE:-3.13

High:3.48

Open:3.16

Low:3.16

Close:3.55

52wk High:9.50

52wk Low:1.98

Shares:11.76M

Float Shares:6.21M

Volume Ratio:1.73

T/O Rate:0.17%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-1.0691

EPS(LYR):-0.7311

ROE:-316.04%

ROA:-96.73%

PB:3.58

PE(LYR):-4.58

Loading ...

Overview Company News Filings

Nasus Pharma Advances NS002 Towards Pivotal Study Following Positive Phase 2; Reports Annual Results and Provides Business Update

What's Going On With Nasus Pharma Stock On Wednesday

Benzinga_recent_news

NYSE American New 52-Week Highs And Lows

Nasus Pharma Stock Hits 52-Week Low - Here's Why

Nasus Pharma’s Positive Phase 2 Data Validates the Speed and Reliability of the NS002 Powder Platform

BRIEF-Nasus Pharma Announces Positive Top Line Data From Phase 2 Clinical Study Of Ns002 Achieves Significantly Superior And Faster Epinephrine Delivery Compared To Epipen® With Accelerated Speed To Therapeutic Threshold

Nasus Pharma announces topline data from Phase 2 clinical study of NS002

Nasus Pharma Phase 2 trial shows NS002 reaches 100 pg/mL epinephrine threshold in 1.69 minutes vs 3.42 minutes for EpiPen

Nasus Pharma Ltd - Pivotal Study Initiation Planned for Q4 2026

THOMSON REUTERS

Nasus Pharma Ltd - Ns002 Shows Favorable Safety Profile With No Serious Adverse Events

THOMSON REUTERS

Nasus Pharma Ltd - Ns002 Reaches Median Peak Concentration in 15 Minutes VS 19.8 Minutes for Epipen

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.atigrzen.com/stock/NSRX/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"NSRX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NSRX\",,,,,undefined,":{"symbol":"NSRX","market":"US","secType":"STK","nameCN":"Nasus Pharma Ltd.","latestPrice":3.35,"timestamp":1789070400000,"preClose":3.55,"halted":0,"volume":10714,"hourTrading":{"tag":"盘后","latestPrice":3.35,"preClose":3.35,"latestTime":"16:10 EDT","volume":7,"amount":23.45,"timestamp":1789071008255,"change":0,"changeRate":0,"amplitude":0},"delay":0,"changeRate":-0.05633802816901401,"floatShares":6214000,"shares":11758900,"eps":-1.06915,"marketStatus":"Post-Mkt","change":-0.2,"latestTime":"09-10 18:04:20 EDT","open":3.16,"high":3.4769,"low":3.16,"amount":36087,"amplitude":0.089268,"askPrice":3.68,"askSize":71,"bidPrice":2.87,"bidSize":100,"shortable":0,"etf":0,"ttmEps":-1.06915,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1789084800000},"marketStatusCode":4,"adr":0,"listingDate":1755057600000,"exchange":"AMEX","adjPreClose":3.55,"preHourTrading":{"tag":"盘前","latestPrice":3.65,"preClose":3.55,"latestTime":"06:16 EDT","volume":1,"amount":3.65,"timestamp":1789035369947,"change":0.1,"changeRate":0.028169,"amplitude":0},"postHourTrading":{"tag":"盘后","latestPrice":3.35,"preClose":3.35,"latestTime":"16:10 EDT","volume":7,"amount":23.45,"timestamp":1789071008255,"change":0,"changeRate":0,"amplitude":0},"volumeRatio":1.731416},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NSRX\",,,,,undefined,":{"symbol":"NSRX","floatShares":6214000,"roa":"-96.73%","roe":"-316.04%","lyrEps":-0.731074,"volumeRatio":1.731416,"shares":11758900,"dividePrice":0,"high":3.4769,"amplitude":0.089268,"preClose":3.55,"low":3.16,"week52Low":1.98,"pbRate":"3.58","week52High":9.5,"institutionHeld":0,"latestPrice":3.35,"committee":0.169591,"eps":-1.06915,"divideRate":0,"volume":10714,"delay":0,"ttmEps":-1.06915,"open":3.16,"prevYearClose":9.15,"prevWeekClose":3.735,"prevMonthClose":4.084,"prevQuarterClose":3.5,"fiveDayClose":3.77,"twentyDayClose":3.2384,"sixtyDayClose":3.15},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NSRX\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NSRX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"NSRX\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":2,"updateTime":1766116800000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/NSRX\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"NSRX","date":"2026-09-09","current":-3.13333,"percent":0.970037,"low":-51.389177,"twenty":-44.647674,"median":-28.389112,"eighty":-6.001389,"high":-4.019591,"avg":-24.780159,"sd":17.640607,"marketCap":45449575},"quantilePoints":[{"date":"2025-08-15","current":-47.343663,"twenty":-48.284655,"median":-47.931783,"eighty":-47.578911,"marketCap":72530491},{"date":"2025-08-22","current":-50.265593,"twenty":-50.691372,"median":-49.082873,"eighty":-48.024103,"marketCap":77006889},{"date":"2025-08-29","current":-47.604473,"twenty":-50.029049,"median":-48.047994,"eighty":-47.509856,"marketCap":72930053},{"date":"2025-09-05","current":-47.370886,"twenty":-49.082873,"median":-47.841017,"eighty":-47.486202,"marketCap":72572198},{"date":"2025-09-12","current":-48.136697,"twenty":-48.519903,"median":-47.66361,"eighty":-47.343663,"marketCap":73745420},{"date":"2025-09-19","current":-47.384488,"twenty":-48.195834,"median":-47.722745,"eighty":-47.36793,"marketCap":72593035},{"date":"2025-09-26","current":-47.604473,"twenty":-48.136697,"median":-47.604473,"eighty":-47.343663,"marketCap":72930053},{"date":"2025-10-03","current":-36.900859,"twenty":-48.077561,"median":-47.51577,"eighty":-47.308794,"marketCap":56532116},{"date":"2025-10-10","current":-45.830394,"twenty":-48.047993,"median":-47.384488,"eighty":-45.830394,"marketCap":70212163},{"date":"2025-10-17","current":-46.835706,"twenty":-47.900153,"median":-47.36793,"eighty":-45.534713,"marketCap":71752301},{"date":"2025-10-24","current":-44.943354,"twenty":-47.900153,"median":-47.314116,"eighty":-44.943354,"marketCap":68853218},{"date":"2025-10-31","current":-46.007802,"twenty":-47.900153,"median":-47.308794,"eighty":-45.239034,"marketCap":70483952},{"date":"2025-11-07","current":-44.647674,"twenty":-47.781881,"median":-47.308794,"eighty":-44.943354,"marketCap":68400236},{"date":"2025-11-14","current":-46.717433,"twenty":-47.722745,"median":-47.22009,"eighty":-44.647674,"marketCap":71571108},{"date":"2025-11-21","current":-41.395195,"twenty":-47.722745,"median":-46.835706,"eighty":-44.351994,"marketCap":63417438},{"date":"2025-11-28","current":-41.395195,"twenty":-47.675437,"median":-46.717433,"eighty":-43.654189,"marketCap":63417438},{"date":"2025-12-05","current":-40.508154,"twenty":-47.6163,"median":-46.155642,"eighty":-42.826285,"marketCap":62058492},{"date":"2025-12-12","current":-38.438395,"twenty":-47.604473,"median":-45.830394,"eighty":-41.395195,"marketCap":58887621},{"date":"2025-12-19","current":-37.669627,"twenty":-47.557164,"median":-45.682553,"eighty":-41.383368,"marketCap":57709868},{"date":"2025-12-26","current":-44.351994,"twenty":-47.509856,"median":-45.298465,"eighty":-41.395195,"marketCap":67947255},{"date":"2026-01-02","current":-43.332802,"twenty":-47.445516,"median":-44.987706,"eighty":-41.359713,"marketCap":82895651},{"date":"2026-01-09","current":-33.62436,"twenty":-47.384488,"median":-44.884218,"eighty":-40.236129,"marketCap":64323401},{"date":"2026-01-16","current":-33.62436,"twenty":-47.379047,"median":-44.647674,"eighty":-40.035066,"marketCap":64323401},{"date":"2026-01-23","current":-31.392839,"twenty":-47.370295,"median":-44.529402,"eighty":-38.570149,"marketCap":60054501},{"date":"2026-01-30","current":-26.473264,"twenty":-47.36793,"median":-44.351994,"eighty":-37.823381,"marketCap":50643354},{"date":"2026-02-06","current":-27.467787,"twenty":-47.363077,"median":-44.351994,"eighty":-35.774424,"marketCap":52545877},{"date":"2026-02-13","current":-34.411045,"twenty":-47.337754,"median":-43.81977,"eighty":-34.753161,"marketCap":65828330},{"date":"2026-02-20","current":-30.724148,"twenty":-47.314116,"median":-43.332802,"eighty":-34.411045,"marketCap":58775295},{"date":"2026-02-27","current":-31.33863,"twenty":-47.308794,"median":-42.873594,"eighty":-33.62436,"marketCap":59950800},{"date":"2026-03-06","current":-30.662699,"twenty":-47.308794,"median":-41.857638,"eighty":-33.151251,"marketCap":58657744},{"date":"2026-03-13","current":-28.389112,"twenty":-47.308794,"median":-41.483899,"eighty":-32.108896,"marketCap":54308372},{"date":"2026-03-20","current":-15.239177,"twenty":-47.308794,"median":-41.395195,"eighty":-31.096524,"marketCap":29152546},{"date":"2026-03-27","current":-4.817647,"twenty":-47.249657,"median":-41.365627,"eighty":-30.724148,"marketCap":28212141},{"date":"2026-04-02","current":-5.099481,"twenty":-47.249657,"median":-40.41945,"eighty":-29.587069,"marketCap":29862560},{"date":"2026-04-10","current":-4.639528,"twenty":-47.202349,"median":-40.212475,"eighty":-29.052754,"marketCap":27169074},{"date":"2026-04-17","current":-4.499542,"twenty":-47.048596,"median":-40.212475,"eighty":-28.102929,"marketCap":26349318},{"date":"2026-04-24","current":-6.799308,"twenty":-46.871188,"median":-39.325435,"eighty":-27.041563,"marketCap":39816747},{"date":"2026-05-01","current":-5.39945,"twenty":-46.741088,"median":-38.438986,"eighty":-25.76289,"marketCap":31619181},{"date":"2026-05-08","current":-6.77931,"twenty":-46.717433,"median":-38.438395,"eighty":-18.667992,"marketCap":39699639},{"date":"2026-05-15","current":-5.939395,"twenty":-46.670125,"median":-36.896469,"eighty":-15.349784,"marketCap":34781099},{"date":"2026-05-22","current":-5.739416,"twenty":-46.374445,"median":-36.254495,"eighty":-7.119275,"marketCap":33610018},{"date":"2026-05-29","current":-6.399349,"twenty":-46.126074,"median":-35.850198,"eighty":-6.399349,"marketCap":37474585},{"date":"2026-06-05","current":-6.47934,"twenty":-46.007802,"median":-35.518691,"eighty":-6.399349,"marketCap":37943017},{"date":"2026-06-12","current":-6.339355,"twenty":-45.901357,"median":-34.571052,"eighty":-6.29136,"marketCap":37123261},{"date":"2026-06-18","current":-6.159373,"twenty":-45.830394,"median":-34.411045,"eighty":-6.175371,"marketCap":36069288},{"date":"2026-06-26","current":-6.599328,"twenty":-45.830394,"median":-33.62436,"eighty":-6.175371,"marketCap":38645666},{"date":"2026-07-02","current":-7.029284,"twenty":-45.771258,"median":-33.505965,"eighty":-6.207368,"marketCap":41163490},{"date":"2026-07-10","current":-6.019387,"twenty":-45.49935,"median":-32.81339,"eighty":-6.167372,"marketCap":35249532},{"date":"2026-07-17","current":-6.139375,"twenty":-45.334124,"median":-32.21535,"eighty":-6.139375,"marketCap":35952180},{"date":"2026-07-24","current":-6.18537,"twenty":-45.191725,"median":-31.392839,"eighty":-6.099379,"marketCap":36221529},{"date":"2026-07-31","current":-6.359353,"twenty":-45.00249,"median":-31.096524,"eighty":-6.099379,"marketCap":37240369},{"date":"2026-08-07","current":-6.77931,"twenty":-44.972922,"median":-30.724148,"eighty":-6.099379,"marketCap":39699639},{"date":"2026-08-14","current":-6.399349,"twenty":-44.943354,"median":-30.662699,"eighty":-6.099379,"marketCap":37474585},{"date":"2026-08-21","current":-4.275233,"twenty":-44.884218,"median":-29.56931,"eighty":-6.079381,"marketCap":45086610},{"date":"2026-08-28","current":-4.552846,"twenty":-44.798471,"median":-29.220042,"eighty":-6.059383,"marketCap":48014312},{"date":"2026-09-04","current":-4.164188,"twenty":-44.647674,"median":-28.450561,"eighty":-6.019387,"marketCap":43915530},{"date":"2026-09-09","current":-4.309651,"twenty":-44.647674,"median":-28.389112,"eighty":-6.001389,"marketCap":45449575}],"updateTime":1789077860365},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NSRX\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2622077033","title":"Nasus Pharma Advances NS002 Towards Pivotal Study Following Positive Phase 2; Reports Annual Results and Provides Business Update","url":"https://stock-news.laohu8.com/highlight/detail?id=2622077033","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622077033?lang=en_us&edition=fundamental","pubTime":"2026-03-25 21:00","pubTimestamp":1774443600,"startTime":"0","endTime":"0","summary":"Recent Phase 2 topline results demonstrate NS002’s potential for best-in-class epinephrine delivery, with statistically significant improvements in early absorption compared to EpiPen; pivotal study p","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/03/25/3262206/0/en/Nasus-Pharma-Advances-NS002-Towards-Pivotal-Study-Following-Positive-Phase-2-Reports-Annual-Results-and-Provides-Business-Update.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4516","X","BK4585","BK4007","BK4588","NSRX","BK4520","BK4006"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620503982","title":"What's Going On With Nasus Pharma Stock On Wednesday","url":"https://stock-news.laohu8.com/highlight/detail?id=2620503982","media":"Benzinga_recent_news","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620503982?lang=en_us&edition=fundamental","pubTime":"2026-03-18 23:11","pubTimestamp":1773846660,"startTime":"0","endTime":"0","summary":"Nasus Pharma stock drops despite fast NS002 results beating EpiPen. Here's why shares are falling and what the data shows.","market":"sh","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/03/18/Peanut-Allergy.jpeg?optimize=medium&dpr=2&auto=webp&width=240","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/03/18/Peanut-Allergy.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/news/health-care/26/03/51328290/whats-going-on-with-nasus-pharma-stock-on-wednesday","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/health-care/26/03/51328290/whats-going-on-with-nasus-pharma-stock-on-wednesday","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_recent_news","symbols":["SMA","BK4007","BK4217","NSRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620607476","title":"NYSE American New 52-Week Highs And Lows","url":"https://stock-news.laohu8.com/highlight/detail?id=2620607476","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620607476?lang=en_us&edition=fundamental","pubTime":"2026-03-17 23:20","pubTimestamp":1773760800,"startTime":"0","endTime":"0","summary":"COMPANY                      SYMBOL       HIGH         VOLUME. -------                      ------       ----         ------. Imperial Oil                 IMO        125.44        209,995. COMPANY                      SYMBOL       LOW          VOLUME. -------                      ------       ----         ------. Credit Suisse Income Fnd     CIK          2.56         35,683. Green Circle Decarbonize     GCDT         1.80          9,147. NFT                          MI         0.5051        192,534. Nasus Pharma                 NSRX         2.70        278,185. Nuburu                       BURU       0.1756     10,216,696. Regentis Biomaterials        RGNT         3.00            810. Serina Therapeutics          SER          1.39         11,876. Copyright (c) 2026 Dow Jones & Company, Inc.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4139","NYSE","BK4107","RGNT","NSRX","AFG","BK4117"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2620749885","title":"Nasus Pharma Stock Hits 52-Week Low - Here's Why","url":"https://stock-news.laohu8.com/highlight/detail?id=2620749885","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2620749885?lang=en_us&edition=fundamental","pubTime":"2026-03-17 01:01","pubTimestamp":1773680460,"startTime":"0","endTime":"0","summary":"Nasus Pharma Ltd.  shares are tumbling on Monday.The company announced topline results from its Phase 2 study of NS002, an investigational intranasal epinephrine powder formulation for the treatment of anaphylaxis , during the premarket session.Soon after the data, the stock price surged as high as $7.29 before falling.The results demonstrated that NS002 has the potential to exceed EpiPen performance.The analysis showed statistically significant improvements in time to therapeutic threshold  and in the proportion of subjects reaching the therapeutic epinephrine threshold within the first minutes following administration.On Monday, at the five-minute mark, 88.4% of subjects receiving NS002 reached the threshold compared to 64.6% with EpiPen, demonstrating a favorable safety profile with no serious adverse events reported.Data released in January showed that NS002 demonstrated a higher mean peak plasma concentration  of 655 pg/ml compared to 548 pg/ml for EpiPen, and achieved peak concen","market":"nz","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/03/16/Genetic-Research-And-Biotech-Science-Con.jpeg?optimize=medium&dpr=2&auto=webp&width=630","type":0,"news_type":0,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/03/16/Genetic-Research-And-Biotech-Science-Con.jpeg?optimize=medium&dpr=2&auto=webp&width=630"],"rights":{"source":"benzinga_hot_news","url":"https://www.benzinga.com/news/health-care/26/03/51276658/nasus-pharma-stock-hits-52-week-low-heres-why","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/health-care/26/03/51276658/nasus-pharma-stock-hits-52-week-low-heres-why","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"benzinga_hot_news","symbols":["BK4007","NSRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619465535","title":"Nasus Pharma’s Positive Phase 2 Data Validates the Speed and Reliability of the NS002 Powder Platform","url":"https://stock-news.laohu8.com/highlight/detail?id=2619465535","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619465535?lang=en_us&edition=fundamental","pubTime":"2026-03-16 21:00","pubTimestamp":1773666011,"startTime":"0","endTime":"0","summary":"WSW, NY, March 16th, 2026, FinanceWire For decades, the treatment of life-threatening allergic reactions has been defined by a paradox: a miracle d...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/newswire/nasus-pharmas-positive-phase-2-data-validates-the-speed-and-reliability-of-the-ns002-powder-platform?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/newswire/nasus-pharmas-positive-phase-2-data-validates-the-speed-and-reliability-of-the-ns002-powder-platform?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4007","NSRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619450368","title":"BRIEF-Nasus Pharma Announces Positive Top Line Data From Phase 2 Clinical Study Of Ns002 Achieves Significantly Superior And Faster Epinephrine Delivery Compared To Epipen® With Accelerated Speed To Therapeutic Threshold","url":"https://stock-news.laohu8.com/highlight/detail?id=2619450368","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619450368?lang=en_us&edition=fundamental","pubTime":"2026-03-16 19:38","pubTimestamp":1773661115,"startTime":"0","endTime":"0","summary":"BRIEF-Nasus Pharma Announces Positive Top Line Data From Phase 2 Clinical Study Of Ns002 Achieves Significantly Superior And Faster Epinephrine Delivery Compared To Epipen With Accelerated Speed To Th","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260316:nTUABFRBH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","NSRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619450556","title":"Nasus Pharma announces topline data from Phase 2 clinical study of NS002","url":"https://stock-news.laohu8.com/highlight/detail?id=2619450556","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619450556?lang=en_us&edition=fundamental","pubTime":"2026-03-16 19:36","pubTimestamp":1773660968,"startTime":"0","endTime":"0","summary":"Nasus Pharma (NSRX) announced top line results from its Phase 2 clinical study of NS002, the Company’s investigational intranasal epinephrine powde...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/nasus-pharma-announces-topline-data-from-phase-2-clinical-study-of-ns002-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/nasus-pharma-announces-topline-data-from-phase-2-clinical-study-of-ns002-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["NSRX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619457039","title":"Nasus Pharma Phase 2 trial shows NS002 reaches 100 pg/mL epinephrine threshold in 1.69 minutes vs 3.42 minutes for EpiPen","url":"https://stock-news.laohu8.com/highlight/detail?id=2619457039","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619457039?lang=en_us&edition=fundamental","pubTime":"2026-03-16 19:31","pubTimestamp":1773660695,"startTime":"0","endTime":"0","summary":"Nasus Pharma reported top-line Phase 2 results for NS002, an investigational intranasal epinephrine powder for anaphylaxis, from an open-label study in 50 healthy adults with a history of allergic rhinitis. After a single administration, the median time to reach 100 pg/mL plasma epinephrine was 1.69 minutes with NS002 versus 3.42 minutes with EpiPen . At 5 minutes, 88.4% of participants receiving NS002 reached the 100 pg/mL threshold compared with 64.6% for EpiPen. The company said no serious adverse events were reported and that it plans to initiate a pivotal study in Q4 2026. The Phase 2 data will be presented in a conference call and webcast.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260316:nNDL9zpKhP:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4112","SG9999014005.SGD","LU2095319765.USD","IE00B64PRP62.GBP","IE00BGHQF748.EUR","NDAQ","IE00BKPKM429.USD","IE00BN0W2V16.EUR","BK4588","LU2210150020.SGD","SG9999014039.USD","BK4585","IE00BN0W2W23.USD","LU0314104364.USD","IE00B3QW5Z07.USD","SG9999014013.SGD","IE00BN0W2T93.GBP","SG9999014021.USD","LU2210149790.SGD","BK4007","NSRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619457249","title":"Nasus Pharma Ltd - Pivotal Study Initiation Planned for Q4 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2619457249","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619457249?lang=en_us&edition=fundamental","pubTime":"2026-03-16 19:30","pubTimestamp":1773660601,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260316:nTUABFRBH:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["NSRX","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619457241","title":"Nasus Pharma Ltd - Ns002 Shows Favorable Safety Profile With No Serious Adverse Events","url":"https://stock-news.laohu8.com/highlight/detail?id=2619457241","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619457241?lang=en_us&edition=fundamental","pubTime":"2026-03-16 19:30","pubTimestamp":1773660601,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260316:nTUABFRBH:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","NSRX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2619457220","title":"Nasus Pharma Ltd - Ns002 Reaches Median Peak Concentration in 15 Minutes VS 19.8 Minutes for Epipen","url":"https://stock-news.laohu8.com/highlight/detail?id=2619457220","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2619457220?lang=en_us&edition=fundamental","pubTime":"2026-03-16 19:30","pubTimestamp":1773660601,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260316:nTUABFRBH:5","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4007","NSRX"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":3,"totalSize":51,"code":"91000000","status":"200"}]}}